Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
BackgroundTo evaluate whether metformin use assuredly alters overall all-cause death in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD).MethodsPubmed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials were systematically searched from inception...
Main Authors: | Yao Hu, Min Lei, Guibao Ke, Xin Huang, Xuan Peng, Lihui Zhong, Ping Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.559446/full |
Similar Items
-
Significance of Metformin Use in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2020-06-01) -
Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001–2018)
by: Linguo Gu, et al.
Published: (2024-03-01) -
Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus
by: Lessey G, et al.
Published: (2019-08-01) -
Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study
by: Min-Ho Kim, et al.
Published: (2021-12-01) -
Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis
by: Wen-Man Zhao, et al.
Published: (2020-01-01)